Los puntos clave no están disponibles para este artículo en este momento.
Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
Streeter et al. (Sun,) studied this question.